Skip to content

Cerevel Therapeutics Holdings, Inc.

Delisted

CIK 1805387fmd_12G3R2BA31Q5ZDBCWCP16ZTHSFManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2019 to Mar 31, 2024, 18 periods

Latest annual · FY2023

Millions
Total revenues
0
Operating income
(447)
Net income
(433)
Free cash flow
(346)

Latest quarter · Q1 FY2024

Millions
Operating income
(143)
Net income
(132)
Free cash flow
(120)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2020 to FY2023
n/m

Cerevel Therapeutics Holdings, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2023FY2022ChangeSource
Revenue$0$010-K 2024-02-27 · proof
Operating income-$447.3 million-$367.8 million10-K 2024-02-27 · proof
Net income-$432.8 million-$351.5 million10-K 2024-02-27 · proof
Cash from operating activities-$342.3 million-$293.2 million10-K 2024-02-27 · proof
Free cash flow-$346.1 million-$297.1 million10-K 2024-02-27 · proof
Total assets$1.2 billion$1 billion+22.2%10-K 2024-02-27 · proof
Total liabilities$569.6 million$496.6 million+14.7%10-K 2024-02-27 · proof
Cash and cash equivalents$416.5 million$136.5 million+205.1%10-K 2024-02-27 · proof
What was Cerevel Therapeutics Holdings, Inc.'s revenue in fiscal 2023?
Cerevel Therapeutics Holdings, Inc. reported revenue of $0 for fiscal 2023 (the year ended Dec 31, 2023), against $0 the year before. Source: the 10-K filed with the SEC on Feb 27, 2024. SEC
What was Cerevel Therapeutics Holdings, Inc.'s operating income in fiscal 2023?
Cerevel Therapeutics Holdings, Inc. reported operating income of -$447.3 million for fiscal 2023 (the year ended Dec 31, 2023), against -$367.8 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2024. SEC
What was Cerevel Therapeutics Holdings, Inc.'s net income in fiscal 2023?
Cerevel Therapeutics Holdings, Inc. reported net income of -$432.8 million for fiscal 2023 (the year ended Dec 31, 2023), against -$351.5 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2024. SEC
What was Cerevel Therapeutics Holdings, Inc.'s cash from operating activities in fiscal 2023?
Cerevel Therapeutics Holdings, Inc. reported cash from operating activities of -$342.3 million for fiscal 2023 (the year ended Dec 31, 2023), against -$293.2 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2024. SEC
What was Cerevel Therapeutics Holdings, Inc.'s free cash flow in fiscal 2023?
Cerevel Therapeutics Holdings, Inc. reported free cash flow of -$346.1 million for fiscal 2023 (the year ended Dec 31, 2023), against -$297.1 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2024. SEC
What are Cerevel Therapeutics Holdings, Inc.'s total assets?
As of Dec 31, 2023, Cerevel Therapeutics Holdings, Inc. reported total assets of $1.2 billion, against $1 billion a year earlier (+22.2%). Source: the 10-K filed with the SEC on Feb 27, 2024. SEC
What are Cerevel Therapeutics Holdings, Inc.'s total liabilities?
As of Dec 31, 2023, Cerevel Therapeutics Holdings, Inc. reported total liabilities of $569.6 million, against $496.6 million a year earlier (+14.7%). Source: the 10-K filed with the SEC on Feb 27, 2024. SEC
What are Cerevel Therapeutics Holdings, Inc.'s cash and cash equivalents?
As of Dec 31, 2023, Cerevel Therapeutics Holdings, Inc. reported cash and cash equivalents of $416.5 million, against $136.5 million a year earlier (+205.1%). Source: the 10-K filed with the SEC on Feb 27, 2024. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1805387&period_type=annual&limit=5"

Information only, not investment advice.